Sangamo Therapeutics (SGMOQ) Asset Writedowns and Impairment (2015 - 2025)

Sangamo Therapeutics' Asset Writedowns and Impairment history runs 4 years deep, the most recent figure standing at $13.2 million for Q4 2025.

• On a quarterly basis, Asset Writedowns and Impairment changed N/A year-over-year to $13.2 million in Q4 2025; TTM through Dec 2025 was $13.2 million, a 139.72% increase from a year earlier, with the FY2025 full-year figure at $13.2 million, up 139.72% from the prior year.
• Asset Writedowns and Impairment climbed to $13.2 million in Q4 2025 per SGMOQ's latest filing, from $1.2 million in the prior quarter.
• Across five years, Asset Writedowns and Impairment topped out at $44.8 million in Q3 2023 and bottomed at $200000.0 in Q4 2023.
• The 3-year median for Asset Writedowns and Impairment is $4.3 million (2023), against an average of $11.3 million.
• Biggest YoY gain for Asset Writedowns and Impairment was 3.55% in 2024; the steepest drop was 3.55% in 2024.
• Year by year, Asset Writedowns and Impairment stood at $200000.0 in 2023, then soared by 486.0% to $1.2 million in 2024, then soared by 1029.27% to $13.2 million in 2025.
• Per Business Quant, the three latest SGMOQ Asset Writedowns and Impairment figures stand at $13.2 million (Q4 2025), $1.2 million (Q2 2024), and $4.3 million (Q1 2024).